Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2016

Open Access 01-12-2016 | Research

Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis

Published in: Health and Quality of Life Outcomes | Issue 1/2016

Login to get access

Abstract

Background

The analysis aimed to examine the impact of pulmonary exacerbations (PEs) and lung function on generic measures of HRQL in patients with cystic fibrosis (CF) using trial-based data.

Methods

In a 48-week randomized, placebo-controlled study of ivacaftor in patients ≥12 years with CF and a G551D-CFTR mutation the relationship between PEs, PE-related hospitalizations and percent predicted forced expiratory volume in one second (ppFEV1) with EQ-5D measures (index and visual analog scale [VAS]) was examined in post-hoc analyses. Multivariate mixed-effects models were employed to describe the association of PEs, PE-related hospitalizations, and ppFEV1 on EQ-5D measures.

Results

One hundred sixty one patients (age: mean 25.5 [SD 9.5] years; baseline ppFEV1: 63.6 [16.4]) contributed 1,214 observations (ppFEV1: no lung dysfunction [n = 157], mild [n = 419], moderate [n = 572], severe [n = 66]). Problems were most frequently reported on pain/discomfort, anxiety/depression, and usual activities EQ-5D items. The mean (SE) EQ-5D index nominally decreased (worsened) with worsening severity of lung dysfunction (P = 0.070): 0.931 (0.023); mild: 0.923 (0.021); moderate: 0.904 (0.018); severe: 0.870 (0.020). 146 PEs were experienced by 72 patients, including 52 PEs (35.6 %) that required hospitalization. Mean EQ-5D index and VAS scores were lowest (worst) within 1 week (before or after PE start) for PEs requiring hospitalization. Pulmonary exacerbations, PE-related hospitalizations, and ppFEV1 were significant predictors of EQ-5D index and VAS.

Conclusions

In a clinical study of patients with CF (≥12 years of age and a G551D-CFTR mutation), PEs, primarily those requiring hospitalization, were associated with low EQ-5D index and VAS scores. The impact of ppFEV1 was relatively smaller. Reducing PEs, in particular those requiring hospitalization, would likely improve HRQL among these patients.

Trial registration

ClinicalTrials.gov, NCT00909532; URL: clinicaltrials.gov, May 26, 2009
Appendix
Available only for authorised users
Literature
1.
Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27(3 Suppl):S217-32. Review. PubMed PMID: 2646490.
2.
Sheppard MN, Nicholson AG. The pathology of cystic fibrosis. Curr Diagn Pathol. 2002;8(1):50–9.
3.
Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. (0066–4219 (Print)).
4.
de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, Paterson N, Jackson M, Lougheed MD, Kumar V, Aaron SD. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011;66(8):680-5. doi:10.​1136/​thx.​2011.​161117. Epub 2011 Jun 15. PubMed PMID: 21680566.
5.
Habib AR, Manji J, Wilcox PG, Javer AR, Buxton JA, Quon BS. A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis. Ann Am Thorac Soc. 2015;12(3):420-8. doi:10.​1513/​AnnalsATS.​201408-393OC. Review. PubMed PMID: 25642976.
6.
Bradley JM, Blume SW, Balp MM, Honeybourne D, Elborn JS. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J. 2013;41(3):571–7.CrossRefPubMed
7.
Yi MS, Britto MT, Wilmott RW, Kotagal UR, Eckman MH, Nielson DW, et al. Health values of adolescents with cystic fibrosis. J Pediatr. 2003;142(2):133–40.CrossRefPubMed
8.
Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121(1):64–72.CrossRefPubMed
9.
Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T, Smyth RL, et al. Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax. 2012;67(10):860–6.CrossRefPubMedPubMedCentral
10.
Busschbach JJ, Horikx PE, van den Bosch JM, Brutel de la Riviere A, de Charro FT. Measuring the quality of life before and after bilateral lung transplantation in patients with cystic fibrosis. Chest. 1994;105(3):911–7.CrossRefPubMed
11.
12.
Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med. 2007;9(10):695–704.CrossRefPubMed
13.
Ramsey SD, Patrick DL, Albert RK, Larson EB, Wood DE, Raghu G. The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. Chest. 1995;108(6):1594–601.CrossRefPubMed
14.
Santana MJ, Feeny D, Ghosh S, Lien DC. Patient-reported outcome 2 years after lung transplantation: does the underlying diagnosis matter? Patient Relat Outcome Meas. 2012;3:79–84.CrossRefPubMedPubMedCentral
15.
Dewitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Lin L, Schulman KA, et al. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. Value Health. 2012;15(2):277–83.CrossRefPubMed
16.
17.
S Acaster, B Pinder, J Osmond, C Mukuria. Mapping the Cystic Fibrosis Questionnaire – Revised (CFQ-R) to a Preference Based Utility Index. 36th European Cystic Fibrosis Society Conference 2013, June 12–15, 2013(Lisbon, Portugal).
18.
Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–72.CrossRefPubMedPubMedCentral
19.
20.
21.
Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ. 2006;15(10):1121–32.CrossRefPubMed
22.
Cleemput I. Economic evaluation in renal transplantation: outcome assessment and cost-utility of non-compliance. Leuven: Acco; 2003.
23.
Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4(3):222–31.CrossRefPubMed
24.
Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socio Econ Plan Sci. 1976;10(3):129–36.CrossRef
25.
S Acaster BP, J Osmond, C Mukuria. Mapping the Cystic Fibrosis Questionnaire – Revised (CFQ-R) to a Preference Based Utility Index. 36th European Cystic Fibrosis Society Conference 2013. 2013;June 12–15, 2013(Lisbon, Portugal).
26.
Czyzewski DI, Mariotto MJ, Bartholomew LK, LeCompte SH, Sockrider MM. Measurement of quality of well being in a child and adolescent cystic fibrosis population. Med Care. 1994;32(9):965-72. PubMed PMID: 8090048.
27.
Powers PM, Gerstle R, Lapey A. Adolescents with cystic fibrosis: family reports of adolescent healthrelated quality of life and forced expiratory volume in one second. Pediatrics. 2001;107(5):E70. PubMed PMID: 11331720.
28.
Abbott J, Dodd M, Webb AK. Different perceptions of disease severity and self care between patients with cystic fibrosis, their close companions, and physician. Thorax. 1995;50(7):794-6. PubMed PMID:7570419; PubMed Central PMCID: PMC474657.
29.
Quittner A, Suthoff E, Rendas-Baum R, Bayliss MS, Sermet-Gaudelus I, Castiglione B, et al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Health Qual Life Outcomes. 2015;13:93.CrossRefPubMedPubMedCentral
30.
Jedlicka-Köhler I, Götz M. Interventional assessment of physical and mental health in children and adolescents with cystic fibrosis. Scand J Gastroenterol Suppl. 1988;143:34-7. PubMed PMID: 3164507.
31.
Charmaz K. Good days, bad days: The self and chronic illness in time. Rutgers University Press; 1991
32.
Moola F, Norman M. ‘Down the rabbit hole’: enhancing the transition process for youth with cystic fibrosis and congenital heart disease by re‐imagining the future and time. Child Care Health Dev. 2011;37(6):841–51.CrossRefPubMed
33.
Jessup M, Parkinson C. “All at sea”: The experience of living with cystic fibrosis. Qual Health Res. 2010;20(3):352–64.CrossRefPubMed
34.
Brazier J, Rowen D. NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values. 2011.
35.
Eidt-Koch D, Mittendorf T, Greiner W. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatr. 2009;9:55.CrossRefPubMedPubMedCentral
36.
Johnson JA, Connolly M, Zuberbuhler P, Brown NE. Health-related quality of life for adults with cystic fibrosis: a regression approach to assessing the impact of recombinant human DNase. Pharmacotherapy. 2000;20(10):1167–74.CrossRefPubMed
37.
Hennessy S, Kind P. Measuring health status in children: Developing and testing a child-friendly version of EQ-5D. In: 19th Plenary Meeting of the EuroQol Group: 2002; York, United Kingdom; 2002.
38.
Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875–86.CrossRefPubMedPubMedCentral
Metadata
Title
Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis
Publication date
01-12-2016
Published in
Health and Quality of Life Outcomes / Issue 1/2016
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-016-0465-z

Other articles of this Issue 1/2016

Health and Quality of Life Outcomes 1/2016 Go to the issue

Research

Effect of psycho-educational interventions on quality of life in patients with implantable cardioverter defibrillators: a meta-analysis of randomized controlled trials

Research

Reliability, validity and clinical correlates of the Quality of Life in Alzheimer’s disease (QoL-AD) scale in medical inpatients

Research

Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL Disease Impact Scale (QDIS®)

Research

Association between physical activity and health-related quality of life in children: a cross-sectional study

Research

Patient Uncertainty Questionnaire-Rheumatology (PUQ-R): development and validation of a new patient-reported outcome instrument for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in a mixed methods study

Research

Psychometric properties of the positive mental health instrument among people with mental disorders: a cross-sectional study